Aerovance, Inc.: Series C $60M

Aerovance (Berkeley, CA) a biopharmaceutical company focused on the development asthma, cystic fibrosis and chronic obstructive pulmonary disease has closed a $60M Series C. Participants in the round included Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & CO.

MAP Pharmaceuticals, Inc.: Series D $50M

MAP Pharmaceuticals (Mountain View, CA) a product based biopharmaceutical focused on developing novel treatments for pediatric asthma and migraine therapy closed a $50M Series D financing. The deal was led by D.E. Shaw & Co. and was joined by Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital Partners, Bay City Capital and Skyline Ventures.

SunTen Phytotech Co., Ltd.: Series B $10M

SunTen Phytotech (Taipei, Taiwan) a botanical drug development company, has raised $10M in Series B funding led by PacLink Capital, Taiwan Global Biofund Venture and 3V SourceOne Venture Capital.